There's not enough information to make that claim.
For example, if a large pharma company, like Gilead, decided to take a large equity stake, along with a partnering deal, it could re-open at a very large premium on the basis that MSB would be de-risked when it comes to funding it's many trials going forward.
Ann: Trading Halt, page-65
-
- There are more pages in this discussion • 869 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.000(0.00%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.20 | $1.18 | $764.3K | 643.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 48854 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 32369 | 8 |
View Market Depth
| Last trade - 10.25am 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |